amlodipine/atorvastatin / Generic mfg. - LARVOL DELTA

SYNERGISTIC LDL-CHOLESTEROL REDUCTION WITH AMLODIPINE AND ATORVASTATIN COMBINATION: A SYSTEMATIC REVIEW AND META-ANALYSIS - Apurva Popat (ACC 2025) - "The combination of amlodipine and atorvastatin is more effective in reducing LDL-C levels compared to atorvastatin monotherapy in patients with hypertension and hypercholesterolemia, unlike ARBs or BBs combined with statins."

Retrospective data • Review • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

A Phase III Randomized, Double-Blind, Active-Controlled, Multicenter Study on the Efficacy and Safety of Ezetimibe/Atorvastatin/Amlodipine Combination in Patients With Comorbid Primary Hypercholesterolemia and Essential Hypertension. (PubMed, Clin Ther) - "Triple combination therapy with Eze/Ato + Aml has effectively reduced the LDL-C and SBP independently, compared with either Eze/Ato or Aml therapies over 8 weeks of treatment period. In terms of safety, there were no significant differences among the 3 treatment groups. This research lays the groundwork for the development of a triple fixed-dose combination in the future, which could improve patient convenience and adherence by reducing pill burden. Clinical Research Information Service (CRIS), Republic of Korea: KCT0006283."

Clinical • Journal • P3 data • Acute Myelogenous Leukemia • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

SPONTANEOUS ISOLATED CELIAC ARTERY DISSECTION FOLLOWING COCAINE USE (SCCM 2025) - "Toxicology was positive for cocaine and fentanyl...Initial treatment included Nicardipine, opioids, Heparin, Aspirin, Atorvastatin, and later Plavix. The patient was discharged stable on dual antiplatelet therapy, Atorvastatin, Amlodipine, and Losartan, with vascular surgery follow-up planned...Surgery is considered for complications like rupture or organ ischemia. While traumatic dissections may require urgent intervention, SICAD treatment protocol remains uncertain due to limited clinical data."

Atherosclerosis • Cardiovascular • Hypertension • Pain

Drug-induced dementia: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database. (PubMed, Ther Adv Neurol Disord) - "Apixaban had the most reports (1631). Disproportionality analyses revealed that rivastigmine, nicergoline, aducanumab, amlodipine/atorvastatin, and dihydroergometrine had the highest risk, based on reporting odds ratio, proportional reporting ratio, and information component. Only valproate and tramadol among the top 50 drugs included a potential dementia risk in their package inserts. This study identified a list of medications associated with dementia risk, many of which lack dementia warnings on their labels. Increased monitoring is necessary for high-risk individuals, and further research is required to clarify these associations and improve patient safety."

Adverse events • Journal • Real-world evidence • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Safety of combined drug use in patients with cardiovascular and cerebrovascular diseases: an analysis based on the spontaneous reporting database of adverse drug reactions in Hubei Province. (PubMed, Front Pharmacol) - "The strongest signal found in this study was jaundice caused by the combination of amlodipine and atorvastatin (Ω 0.025:3.08, lift: 1116.69, conviction: 1.75)...Patients under 60 years old had a palpitations signal when combining eritrea bei sha Tanzania and felodipine (Ω 0.025:0.41, lift: 14.65, conviction: 3.8), and an erythema signal when combining nifedipine (Ω 0.025:0.23, lift: 8.17, conviction: 1.077)...Five adverse events associated with aspirin-induced bleeding were identified. Notably, different adverse drug reactions were observed in different populations, suggesting the need for future studies to expedite the development of personalized medicine."

Adverse drug reaction • Journal • Cardiovascular • CNS Disorders • Dermatology • Hematological Disorders • Hepatology • Vascular Neurology

Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese with Hypertension and Atrial Fibrillation (clinicaltrials.gov) - P4 | N=1200 | Active, not recruiting | Sponsor: Shanghai Jiao Tong University School of Medicine | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Enrollment closed • Trial completion date • Trial primary completion date • Atrial Fibrillation • Cardiovascular • Hypertension

The 10 top prescribed medicines in Germany from 1985 to 2022: pharmacological analysis. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "The ten most important medicines in 2022, accounting for over 41% of all prescribed daily doses, were ramipril, candesartan, pantoprazole, amlodipine, atorvastatin, levothyroxine, torasemide, simvastatin, bisoprolol, and metoprolol. Overall, this is the most comprehensive long-term analysis of drug prescriptions in Germany. Our data is helpful for predicting drug prescriptions and for preventing future drug shortages not only in Germany but also worldwide."

Journal

Real-World Statin Use and 10-Year Atherosclerotic Cardiovascular Disease Risk in Patients With Biopsy-Confirmed Metabolic Dysfunction Associated Steatohepatitis in an Integrated Delivery Network (ACG 2024) - "3,442 MASH patients had data available to calculate ASCVD risk – 1,359 (39.5%) statin users and 2,083 (60.5%) nonusers. Baseline type 2 diabetes, smoker, and hypertension rates were 29.4%, 51.1%, and 97.2% in statin users and 22.6%, 30.8%, and 36.7% in nonusers. Identified statins included atorvastatin (n=756), amlodipine/atorvastatin (n=3), fluvastatin (n=1), lovastatin (n=12), pitavastatin (n=1), pravastatin (n=152), rosuvastatin (n=290), simvastatin (n=136), and simvastatin/ezetimibe (n=2)."

Biopsy • Clinical • Real-world • Real-world evidence • Atherosclerosis • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Diabetes • Dyslipidemia • Heart Failure • Hepatology • Hypertension • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Type 2 Diabetes Mellitus

Dengue Virus-Induced Acute Interstitial Nephritis (KIDNEY WEEK 2024) - "Home medications were Amlodipine, Atorvastatin and Sildenafil...The patient was discharged on Prednisone taper for two weeks...There have been reports of ATN secondary to severe rhabdomyolysis in dengue fever but there has not been any reported case of AIN. Even though amlodipine has been reported to cause interstitial nephritis, the patient had been taking it for more than a year before the presentation, without any worsening of his renal functions.."

Acute Kidney Injury • Cardiovascular • Dengue Fever • Dyslipidemia • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Inflammation • Musculoskeletal Pain • Nephrology • Pain • Renal Disease

Phase 1 Evaluation of the Bioequivalence and Drug-Drug Interaction Potential of a Novel Fixed-Dose Combination of Ezetimibe, Atorvastatin, and Amlodipine. (PubMed, Clin Pharmacol Drug Dev) - "Geometric mean ratios (FDC to individual formulations) and 90% confidence intervals of area under the time-concentration curve at steady state during dosing interval (AUCτ, ss) and maximum concentration at steady state (Cmax, ss) or amlodipine, atorvastatin, and ezetimibe were all within the bioequivalent range (0.8-1.25), confirming bioequivalence. Moreover, the FDC of ezetimibe, atorvastatin, and amlodipine exhibited comparable tolerability to corresponding individual formulations."

Journal • P1 data • Cardiovascular

Transmural changes of microscopic colitis using intestinal ultrasound: a case report (AGW-GESA 2024) - "Her past medical history included high cholesterol, hypertension and anxiety, for which she was prescribed longstanding atorvastatin, amlodipine and venlafaxine...The patient was commenced on intravenous hydrocortisone 100mg QID with excellent clinical (bowel frequency reduced to 2) and biochemical response over a 48-hour period and was transitioned to prednisolone and later budesonide... Beyond diagnosis, this case further demonstrates the potential for GIUS to monitor response to treatment of collagenous colitis. We would advocate for the routine use of GIUS in the evaluation of patients with chronic diarrhoeal illnesses given its non-invasive nature and utility in serial evaluation."

Case report • Clinical • Acute Kidney Injury • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Hypertension • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Nephrology • Psychiatry • Renal Disease • CRP

STOP-PA: Statin Combined With Amlodipine Treats Primary Aldosteronism (clinicaltrials.gov) - P4 | N=150 | Not yet recruiting | Sponsor: Third Military Medical University

New P4 trial • Cardiovascular • Endocrine Disorders • Hypertension

Pharmacokinetic Comparison of a Fixed-Dose Combination of Candesartan Cilexetil/Amlodipine/Atorvastatin Versus Co-administration of Individual Formulations in Healthy Participants. (PubMed, Adv Ther) - P1 | "The Cmax and AUClast values of candesartan cilexetil/amlodipine/atorvastatin 16/10/40 mg and 16/5/20 mg, respectively, were within the BE ranges. There were no clinically significant differences in safety between the two formulations."

Journal • PK/PD data • Cardiovascular

Clinical Benefit of Fixed-Dose Combination of Amlodipine and Potent Atorvastatin in Patients With Concomitant Hypertension and Hypercholesterolemia. (PubMed, J Am Heart Assoc) - "Among patients with concomitant hypertension and hypercholesterolemia, treatment with an FDC of amlodipine and high-dose atorvastatin led to a lower risk of a composite of cardiovascular outcomes than treatment with the free combination or a similar FDC with a lower dose of atorvastatin."

Journal • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders • Myocardial Infarction

Drug-induced liver injury secondary to Rivaroxaban masquerading in Acute Cholangitis & Pancreatitis (APASL 2024) - "Three potential drugs were considered: Amlodipine, atorvastatin and Rivaroxaban (Table 2) Review of drug history revealed that rivaroxaban was recently started and held off for ERCP. Liver biopsy (Figure 1) showed hepatocellular injury lobular inflammation, hepatocyte drop-out and apoptotic hepatocytes involving Zones 3 and 2 lobular parenchyma, in keeping with clinical impression of DILI with rivaroxaban having both highest RUCAM and likelihood score (Table 2) This is further confirmed by improvement of transaminases upon cessation of rivaroxaban Clinical Significance: Rivaroxaban is a potential cause for DILI that physicians should be aware of."

Atrial Fibrillation • Autoimmune Hepatitis • Cardiovascular • Coronary Artery Disease • Heart Failure • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Failure • Pain • Pancreatitis

Audio/Podcasts and Art: A Collaboration Between the Renal Patient Support Group (RPSG) and the Kidney Disease and Renal Support Group (KDARs) for Kids and ZtormLabostix Productions (KIDNEY WEEK 2023) - "Case Description 60-year-old woman with diabetes mellitus type 2, hypertension, hyperlipidemia, chronic osteoarthritis, chronic pelvic pain, and history of rheumatic heart fever was referred for intermittent hypercalcemia, ranging between 9.9-11.2 mg/dL.Medications: amlodipine, atorvastatin, fenofibrate, glimerpiride, metformin, metoprolol, magnesium oxide, loratidine.Vital signs: height 160 cm, weight 85.5 kg, blood pressure 145/62 mmHg, pulse 72 bpm, 36.2oC.Physical exam: within normal limits.Other laboratory findings: Serum phosphorus ranges between 2.6-3.8 mg/dL (2.4-4.7 mg/dL), albumin 4.1 g/dL (3.5-4.8 g/dL), PTHrp 16 pg/mL, (14-27 pg/mL), 1,25D3 ranges between 67-82 pg/mL (18-72), PTH ranges between 28-49 pg/mL (15-65). Hypercalcemia has a wide differential diagnosis. A thorough search for its cause is warranted for direct and specific therapy."

Clinical • Cardiovascular • Diabetes • Dyslipidemia • Endocrine Disorders • Gastrointestinal Disorder • Gynecology • Hypertension • Immunology • Metabolic Disorders • Musculoskeletal Pain • Nephrology • Osteoarthritis • Pain • Renal Disease • Rheumatology • Type 2 Diabetes Mellitus

Identification of Drugs Acting as Perpetrators in Common Drug Interactions in a Cohort of Geriatric Patients from Southern Italy and Analysis of the Gene Polymorphisms That Affect Their Interacting Potential. (PubMed, Geriatrics (Basel)) - "We provided a list of the allelic variants influencing the activity of drug perpetrators in older adults which should be included in pharmacogenomics-oriented CDSSs to be used in geriatric medicine."

Journal • Geriatric Disorders • CYP2C19 • CYP2C9 • CYP3A4

The influence of atorvastatin, amlodipine and ethoxidol on ubiquinol and ubiquinone endogenous plasma concentrations in patients with chronic heart failure. (PubMed, Curr Drug Metab) - "Amlodipine is able to neutralize the negative effect of atorvastin on the redox balance of CoQ10 in patients with CHF. An additional prescription of the antioxidant ethoxidol to standard therapy for patients with CHF was substantiated. Determination of the redox state of CoQ10 in plasma can be used to diagnose and assess the degree of oxidative stress in patients with cardiovascular diseases, as well as to assess the efficacy and safety of ongoing pharmacotherapy."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia. (PubMed, J Clin Hypertens (Greenwich)) - P4 | "There was no significant difference in the adverse events rates between RSV 10 mg/AML 5 mg, RSV 20 mg/AML 5 mg, and ATV 20 mg/AML 5 mg. In conclusion, while maintaining safety, RSV 10 mg/AML 5 mg and the RSV 20 mg/AML 5 mg more effectively reduced LDL-C compared with the ATV 20 mg /AML 5 mg (Clinical trial: NCT03951207)."

Journal • P4 data • Acute Myelogenous Leukemia • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

Atorvastatin and Fluvastatin Potentiate Blood Pressure Lowering Effect of Amlodipine through Vasorelaxant Phenomenon. (PubMed, Medicina (Kaunas)) - "A positive relaxing effect on 80 mM KCl induced contractions were further confirmed in the absence and presence of atorvastatin and fluvastatin by constructing calcium concentration response curves (CCRCs) while using verapamil as a standard calcium channel blocker...These statins also inhibit the effects of NE induced contractions. The study also confirms that atorvastatin and fluvastatin potentiate blood pressure lowering effects in hypertensive rats."

Journal • Cardiovascular • Hypertension

CODE STEMI Due to Excessive Ingestion of TUMS (ENDO 2023) - "His medications included hydrochlorothiazide, losartan, amlodipine, atorvastatin, glimepiride, and famotidine. Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*"

Atrial Fibrillation • Cardiovascular • Constipation • Diabetes • Diabetic Nephropathy • Endocrine Disorders • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Hypertension • Metabolic Disorders • Myocardial Infarction • Oncology • Pain • Renal Disease

A New method for simultaneous qualitative and quantitative determination of amlodipine besylate and atorvastatin calcium in bulk and pharmaceutical formulations using transmission FT-IR spectroscopy. (PubMed, Heliyon) - "Likewise, the acquired results were compared with the HPLC method. And the t- and F- tests were calculated and compared with the theoretical values, which indicate the similarity of results in both developed and reported methods."

Journal • Acute Myelogenous Leukemia

A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE) (clinicaltrials.gov) - P4 | N=9971 | Active, not recruiting | Sponsor: Monash University | Recruiting ➔ Active, not recruiting | Trial primary completion date: Dec 2022 ➔ Dec 2025

Enrollment closed • Trial primary completion date • Alzheimer's Disease

Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial Fibrillation (clinicaltrials.gov) - P4 | N=1200 | Recruiting | Sponsor: Shanghai Jiao Tong University School of Medicine | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Atrial Fibrillation • Cardiovascular • Hypertension

Blood Pressure and Lipids Reduction in High Risk Elderly Patients With Isolated Systolic Hypertension (clinicaltrials.gov) - P4 | N=480 | Recruiting | Sponsor: Shanghai Jiao Tong University School of Medicine | Trial completion date: Jun 2024 ➔ Jun 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • Cardiovascular • Hypertension